Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area. Issue 1 (January 2022)
- Record Type:
- Journal Article
- Title:
- Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area. Issue 1 (January 2022)
- Main Title:
- Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area
- Authors:
- Elli, Luca
Facciotti, Federica
Lombardo, Vincenza
Scricciolo, Alice
Sanders, David S.
Vaira, Valentina
Barisani, Donatella
Vecchi, Maurizio
Costantino, Andrea
Scaramella, Lucia
dell'Osso, Bernardo
Doneda, Luisa
Roncoroni, Leda - Abstract:
- Abstract: Background and aim: How symptoms and antibodies related to SARS-CoV-2 infection develop in patients with celiac disease (CD) is unclear. We aimed to investigate the impact of SARS-CoV-2 infection in CD patients. Methods: CD patients were interviewed about the development of COVID-19 symptoms, compliance with anti-virus measures and adherence to a gluten-free diet (GFD). The presence of anti-SARS-CoV-2 IgG and IgA (anti-RBD and N proteins) was compared to that in non-CD subjects. Expression of the duodenal ACE2 receptor was investigated. When available, data on duodenal histology, anti-tissue transglutaminase IgA (tTGA), comorbidities and GFD adherence were analyzed. Results: Of 362 CD patients, 42 (12%) reported COVID-19 symptoms and 21% of these symptomatic patients presented anti-SARS-CoV-2 Ig. Overall, 18% of CD patients showed anti-SARS-CoV-2 Ig versus 25% of controls ( p = 0.18). CD patients had significantly lower levels of anti-N IgA. tTGA, duodenal atrophy, GFD adherence or other comorbidities did not influence symptoms and/or antibodies. The ACE2 receptor was detected in the non-atrophic duodenal mucosa of patients; atrophy was associated with lower expression of the ACE2 receptor. Conclusion: CD patients have an anti-SARS-CoV-2 Ig profile similar to non-celiac controls, except for anti-N IgA. No risk factors were identified among CD parameters and GFD adherence.
- Is Part Of:
- Digestive and liver disease. Volume 54:Issue 1(2022)
- Journal:
- Digestive and liver disease
- Issue:
- Volume 54:Issue 1(2022)
- Issue Display:
- Volume 54, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 54
- Issue:
- 1
- Issue Sort Value:
- 2022-0054-0001-0000
- Page Start:
- 3
- Page End:
- 9
- Publication Date:
- 2022-01
- Subjects:
- ACE2 receptor -- Celiac disease -- COVID-19 -- Gluten -- SARS-CoV-2 -- Small bowel
Digestive organs -- Diseases -- Periodicals
Liver -- Diseases -- Periodicals
616.33005 - Journal URLs:
- http://www.sciencedirect.com/science/journal/15908658 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.dld.2021.08.027 ↗
- Languages:
- English
- ISSNs:
- 1590-8658
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3588.345600
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20293.xml